Indobufen oral solid preparation and preparation method thereof
By using a combination of biphasic release structure and surfactant in oral solid preparations of indobufen, the problem of incomplete dissolution and release of indobufen is solved, rapid onset and long-term effects are achieved, and bioavailability is improved and preparation feasibility.
Patent Information
- Application Number
- CN202411241967.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-15
AI Technical Summary
The dissolution and release of indobufen oral solid preparations is incomplete, resulting in a short-lasting efficacy and unstable clinical bioavailability. The existing technology means are costly and complex, making them unsuitable for large-scale production.
Indobufen oral solid preparation using a biphase release structure, the drug is increased by adding surfactant to the drug-containing fast-release part and the drug-containing sustained-release part respectively, and the drug-containing solubility is improved by atomizing method, and prepared in combination with tableting process to achieve rapid start-up. Effective and long-term effect.
It improves the bioavailability stability of indobufen, solves the problems of short-lasting efficacy and poor compliance, simplifies the preparation process, reduces costs, and achieves the biphasic release characteristics.
Smart Images

Figure CN118948788A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical preparations, and more specifically, to an oral solid preparation of indobufen and a preparation method thereof. Background Art
[0002] Atherosclerosis (AS) is a common disease that seriously endangers human health. Atherosclerosis is also the main cause of coronary heart disease, cerebral infarction, and peripheral vascular disease. Atherosclerosis is caused by the combined action of multiple factors, and the pathogenesis is complex. Pathological thrombosis caused by platelet aggregation is the main cause of the clinical manifestations of atherosclerotic thrombotic diseases. Indobufen is an isoindoline phenylbutyric acid derivative and a drug that inhibits platelet aggregation. It was originally developed by Farmfalia Carlo Erba in Italy and introduced to my country by Bohua Pharmaceutical in 2005. It can be used for arteriosclerotic ischemic cardiovascular lesions, ischemic cerebrovascular lesions and peripheral arterial lesions, dyslipidemia and diabetes. It can also be used to prevent thrombosis during extracorporeal circulation surgery. As one of the important therapeutic drugs for cardiovascular and cerebrovascular diseases, indobufen has now become an alternative drug for aspirin intolerance.
[0003] Indobufen has low solubility in water, unstable clinical bioavailability, and unsatisfactory therapeutic effects due to individual differences among patients. In particular, oral solid preparations of indobufen are prone to drug accumulation in the body due to their slow clearance rate, which can lead to bleeding complications and increase the risk of frequent gastrointestinal disorders.
[0004] Indobufen tablets are common oral tablets, taken twice a day, 100-200 mg (1 / 2 tablet to 1 tablet) each time, orally after meals. Due to the low solubility of indobufen in water, its clinical bioavailability is unstable.
[0005] For APIs with poor solubility, the existing conventional technical means are:
[0006] (1) Direct addition of the solubilizer for granulation may result in uneven distribution of the solubilizer, resulting in poor solubilization effect and failure to achieve the effect of improving solubility.
[0007] (2) Solid dispersions (such as CN105853364B) can be prepared together with some solubilizing excipients to achieve the solubilization effect. However, the preparation process is slightly complicated and requires special process equipment, which is costly and not conducive to large-scale production. Summary of the invention
[0008] The present invention aims to overcome at least one defect of the above-mentioned prior art and provide an oral solid preparation of indobufen and a preparation method thereof, so as to solve the problems of incomplete dissolution and release and unsustainable therapeutic effect.
[0009] The first aspect of the present invention is to provide an oral solid preparation of indobufen, comprising a drug-containing rapid-release portion and a drug-containing sustained-release portion;
[0010] The drug-containing immediate-release portion includes a first indobufen active ingredient, a first filler, a first surfactant, a first binder, a first lubricant and a disintegrant;
[0011] The drug-containing sustained-release portion comprises a second indobufen active ingredient, a second filler, a second surfactant, a second adhesive, a second lubricant and a sustained-release material.
[0012] The present invention distributes the indobufen active ingredient into a drug-containing sustained-release portion and a drug-containing rapid-release portion respectively, so as to prepare an indobufen oral solid preparation with a biphasic release characteristic. The drug-containing rapid-release portion can rapidly release the first indobufen active ingredient to achieve a rapid onset of action, and the drug-containing sustained-release portion can slowly release the second indole active ingredient to extend the administration time and achieve a long-term onset of action. Therefore, the indobufen oral solid preparation of the present invention can have both the effects of rapid onset of action and long-lasting action, which helps to reduce the number of times of administration and improve patient compliance.
[0013] Furthermore, the weight ratio of the first indobufen active ingredient to the second indobufen active ingredient is 1:2-1:4.
[0014] In the present invention, the indobufen active ingredients in the immediate-release portion and the sustained-release portion reach an optimal distribution ratio, so that after the patient ingests the indobufen oral solid preparation, the indobufen active ingredients in the immediate-release portion are sufficient to achieve a rapid onset of effect on the patient, and at the same time, the indobufen active ingredients in the sustained-release portion are also sufficient to meet the requirements of long-term drug administration for the patient.
[0015] Furthermore, the first surfactant is selected from one or more of Tween-80, polyoxyethylene castor oil, polyethylene glycol, polysorbates, glycerol, sodium lauryl sulfate, monocaprylic acid glyceryl, stearic acid polyethylene glycol glyceryl ester, caprylic and capric mono- and di-glycerides.
[0016] Furthermore, the content of the first surfactant in the drug-containing rapid-release portion is 0.1-5% by weight.
[0017] The dosage of the first surfactant of the present invention can improve the dissolution rate of the indobufen active ingredient in the rapid-release part of the drug and make the dissolution rate moderate, which can not only achieve the effect of rapid drug administration, but also avoid the safety risk of excessive drug administration to patients.
[0018] Furthermore, the second surfactant is selected from one or more of Tween-80, polyoxyethylene castor oil, polyethylene glycol, polysorbates, glycerol, sodium lauryl sulfate, monocaprylic acid glyceryl, stearic acid macrogol glyceryl ester, caprylic and capric mono- and di-glycerides.
[0019] Furthermore, in terms of weight percentage, the content of the second surfactant in the drug-containing sustained-release portion is 0.1-5%.
[0020] The dosage of the second surfactant of the present invention can improve the dissolution rate of the active ingredient of indobufen in the drug-containing sustained-release part, so that the active ingredient is completely dissolved and released, which is beneficial to the in vivo absorption of the drug.
[0021] Furthermore, the content of the first indobufen active ingredient in the drug-containing immediate-release portion is 10-30% by weight; and / or,
[0022] The content of the second indobufen active ingredient in the drug-containing sustained-release portion is 15-35%.
[0023] By adopting the indobufen active ingredient content ratio of the present invention, the indobufen active ingredient in the drug-containing rapid-release portion can meet the purpose of rapid administration to patients to achieve rapid onset of effect, and can also ensure that the indobufen active ingredient in the drug-containing rapid-release portion can meet the purpose of long-lasting effect on patients, thereby facilitating the in vivo absorption of the drug and improving the stability of bioavailability.
[0024] Furthermore, the disintegrant is selected from one or more of low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, calcium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and pregelatinized starch.
[0025] Furthermore, the content of the disintegrant in the drug-containing rapid-release portion is 2-8% by weight.
[0026] Furthermore, the sustained-release material is selected from one or more of hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, xanthan gum, sodium alginate, carbomer or polyethylene oxide.
[0027] Furthermore, in terms of weight percentage, the content of the sustained-release material in the drug-containing sustained-release portion is 10-50%.
[0028] Furthermore, the first filler is selected from one or more of lactose, microcrystalline cellulose, mannitol, starch or pregelatinized starch.
[0029] Furthermore, in terms of weight percentage, the content of the first filler in the drug-containing immediate-release portion is 40-80%, preferably 50-70%.
[0030] Furthermore, the second filler is selected from one or more of lactose, microcrystalline cellulose, mannitol, starch or pregelatinized starch.
[0031] Furthermore, in terms of weight percentage, the content of the second filler in the drug-containing sustained-release portion is 20-60%, preferably 30-50%.
[0032] Furthermore, the first binder is selected from one or more of hydroxypropyl methylcellulose, polyvinyl pyrrolidone, hydroxypropyl methylcellulose or hydroxypropyl cellulose.
[0033] Furthermore, the content of the first binder in the drug-containing rapid-release portion is 2-10% by weight.
[0034] Furthermore, the second binder is selected from one or more of hydroxypropyl methylcellulose, polyvinyl pyrrolidone, hydroxypropyl methylcellulose or hydroxypropyl cellulose.
[0035] Furthermore, in terms of weight percentage, the content of the second binder in the drug-containing sustained-release portion is 2-10%.
[0036] Furthermore, the first lubricant is selected from one or more of talc, hydrogenated vegetable oil, sodium stearyl fumarate or magnesium stearate.
[0037] Furthermore, in terms of weight percentage, the content of the first lubricant in the drug-containing rapid-release portion is 0.2-3%.
[0038] Furthermore, the second lubricant is selected from one or more of talc, hydrogenated vegetable oil, sodium stearyl fumarate or magnesium stearate.
[0039] Furthermore, in terms of weight percentage, the content of the second lubricant in the drug-containing sustained-release portion is 0.2-3%.
[0040] The second aspect of the present invention is to provide a method for preparing the indobufen oral solid preparation, comprising the following steps:
[0041] Weighing the active ingredient of indobufen, a filler, a disintegrant, and a binder in the drug-containing immediate-release part, sieving and premixing them to obtain a drug-containing immediate-release premix excipient, adding a surfactant to the drug-containing immediate-release premix excipient for wet granulation, then sequentially performing wet granulation, drying, and dry granulation, and finally adding a prescribed amount of a lubricant for total mixing to obtain drug-containing immediate-release granules;
[0042] The active ingredient of the drug-containing sustained-release indobufen, a filler, a disintegrant, and a binder are weighed, sieved, and premixed to obtain a drug-containing sustained-release premix excipient, a surfactant is added to the drug-containing sustained-release premix excipient for wet granulation, and then wet granulation, drying, and dry granulation are sequentially performed, and finally a prescribed amount of lubricant is added for total mixing to obtain drug-containing sustained-release granules;
[0043] The prescribed amount of drug-containing sustained-release layer particles are placed in a tablet press die and pre-pressed; then the prescribed amount of drug-containing immediate-release layer particles are placed in the die and pressed into tablets, followed by coating and packaging to obtain an oral solid preparation of indobufen.
[0044] Furthermore, adding the first surfactant to the drug-containing immediate-release premix excipient comprises: dissolving the first surfactant in a solvent to prepare a mixed solution, and then adding the mixed solution to the drug-containing immediate-release premix excipient in a spraying manner; and / or,
[0045] Adding the second surfactant to the drug-containing sustained-release premix excipient comprises: dissolving the second surfactant in a solvent to prepare a mixed solution, and then adding the mixed solution to the drug-containing sustained-release premix excipient in a spraying manner.
[0046] The present invention adopts an atomization method to add a surfactant, which can improve the solubility of the indobufen active ingredient, make the dissolution and release more complete, facilitate the in vivo absorption of the drug, and improve the stability of bioavailability.
[0047] Compared with the prior art, the present invention has the following beneficial effects:
[0048] 1) The oral solid preparation of indobufen provided by the present invention has the characteristics of biphasic release, which can solve the problems of short-lasting efficacy, poor patient compliance and insufficient clinical safety;
[0049] 2) By adding surfactants to the drug-containing immediate-release portion and the drug-containing sustained-release portion, the solubility of the active ingredient of indobufen is improved, and the problems of low solubility of indobufen in water, incomplete dissolution and release in vitro, and unstable clinical bioavailability are solved. In particular, the surfactant is added by atomization to further improve the dissolution rate;
[0050] 3) The preparation process of the present invention is simple, which helps to improve the process operability, repeatability and feasibility and reduce costs. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 This is the indobufen dissolution curve of the indobufen oral solid preparation provided in Example 1.
[0052] Figure 2 This is the indobufen dissolution curve of the indobufen oral solid preparation provided in Example 2.
[0053] Figure 3 This is the indobufen dissolution profile of the indobufen oral solid preparation provided in Example 3.
[0054] Figure 4 This is the indobufen dissolution profile of the indobufen oral solid preparation provided in Example 4.
[0055] Figure 5 This is the indobufen dissolution profile of the indobufen oral solid preparation provided in Example 5.
[0056] Figure 6 This is the indobufen dissolution curve of the indobufen oral solid preparation provided in Comparative Example 1.
[0057] Figure 7 This is the indobufen dissolution curve of the indobufen oral solid preparation provided in Comparative Example 2.
[0058] Figure 8 This is the indobufen dissolution curve of the indobufen oral solid preparation provided in Comparative Example 3.
[0059] Fig. 9 This is the indobufen dissolution curve of the indobufen oral solid preparation provided in Comparative Example 4.
[0060] Fig.10 This is the indobufen dissolution curve of the indobufen oral solid preparation provided in Comparative Example 5.
[0061] Fig.11 This is the indobufen dissolution curve of the indobufen oral solid preparation provided in Comparative Example 6.
[0062] Fig.12 This is the indobufen dissolution curve of the indobufen oral solid preparation provided in Comparative Example 7.
[0063] Fig.13 This is the indobufen dissolution curve of the indobufen oral solid preparation provided in Comparative Example 8. DETAILED DESCRIPTION
[0064] The first aspect of the present invention is to provide an oral solid preparation of indobufen, comprising a drug-containing rapid-release portion and a drug-containing sustained-release portion;
[0065] The drug-containing immediate-release portion includes a first indobufen active ingredient, a first filler, a first surfactant, a first binder, a first lubricant, and a disintegrant;
[0066] The drug-containing sustained-release portion comprises a second indobufen active ingredient, a second filler, a second surfactant, a second binder, a second lubricant and a sustained-release material.
[0067] In specific implementation, in order to facilitate preparation, the drug-containing rapid-release granules and the drug-containing sustained-release granules can be combined together by tableting, so that the drug-containing rapid-release granules form the drug-containing rapid-release part, and the drug-containing sustained-release granules form the drug-containing sustained-release part, thereby obtaining the indobufen oral solid preparation of the present invention.
[0068] The present invention distributes the indobufen active ingredient into a drug-containing sustained-release portion and a drug-containing rapid-release portion respectively to prepare an indobufen oral solid preparation with a biphasic release characteristic. After a patient takes the indobufen oral solid preparation of the present invention, the drug-containing rapid-release portion can rapidly release the first indobufen active ingredient to achieve a rapid onset of action. Meanwhile, the drug-containing sustained-release portion can slowly release the second indole active ingredient, thereby extending the administration time and achieving a long-term onset of action. Therefore, the indobufen oral solid preparation of the present invention can have both the effects of rapid onset of action and long-lasting action, which helps to reduce the number of times of administration, improve patient compliance, and improve the bioavailability of indobufen.
[0069] In some embodiments, the weight ratio of the first indobufen active ingredient to the second indobufen active ingredient is 1:2-1:4, preferably 1:2.5-1:3.5. In specific implementations, the weight ratio of the first indobufen active ingredient to the second indobufen active ingredient can be set to 1:2, 1:2.5, 1:3, 1:3.5, 1:4, etc.
[0070] The test found that when the weight ratio of the first indobufen active ingredient to the second indobufen active ingredient is greater than 1:2, the proportion of indobufen active ingredients in the immediate release portion is relatively high, resulting in a faster dissolution rate of the drug ingredients, which may pose a safety risk to patients; and when the weight ratio of the first indobufen active ingredient to the second indobufen active ingredient is less than 1:4, the proportion of indobufen active ingredients in the sustained release portion is relatively high, resulting in a slower dissolution rate of the drug ingredients, which cannot meet the purpose of rapid onset of effect on patients, and the drug dissolution within 24 hours is incomplete, which has an adverse effect on the bioavailability of the drug. It can be seen that the indobufen active ingredients of the drug-containing immediate release portion and the drug-containing sustained release portion of the present embodiment reach a better distribution ratio, so that after the patient ingests the indobufen oral solid preparation, the indobufen active ingredients in the drug-containing immediate release portion are sufficient to achieve a rapid onset of effect on the patient, and at the same time, the indobufen active ingredients in the drug-containing sustained release portion are sufficient to meet the requirements of long-term administration to the patient.
[0071] Optionally, the first surfactant is selected from one or more of Tween-80, polyoxyethylene castor oil, polyethylene glycol, polysorbates, glycerol, sodium lauryl sulfate, monocaprylic acid glyceryl, stearic acid macrogol glyceryl ester, caprylic and capric mono- and di-glycerides.
[0072] In some embodiments, the content of the first surfactant in the drug-containing immediate-release portion is 0.1-5%, preferably 0.2-3.0%, by weight percentage. In specific implementation, it can be set to 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, etc.
[0073] The test found that when the content of the first surfactant in the drug-containing rapid-release portion is less than 0.1%, the dissolution rate of the indobufen active ingredient in a short period of time is low, the rapid-release effect is poor, and the requirement for rapid onset of action for patients may not be met; when the content of the first surfactant in the drug-containing rapid-release portion is greater than 5%, the rapid-release of the indobufen active ingredient is excessive, which may pose a safety hazard to patients. It can be seen that the dosage of the first surfactant of the present invention can increase the dissolution rate of the indobufen active ingredient in the drug-containing rapid-release portion and make the dissolution rate moderate, which can not only achieve a rapid drug administration effect, but also avoid the safety risk of excessive drug administration to patients.
[0074] Optionally, the second surfactant is selected from one or more of Tween-80, polyoxyethylene castor oil, polyethylene glycol, polysorbates, glycerol, sodium lauryl sulfate, monocaprylic acid glyceryl, stearic acid macrogol glyceryl ester, caprylic and capric mono- and di-glycerides.
[0075] In some embodiments, the content of the second surfactant in the drug-containing sustained-release portion is 0.1-5% by weight, preferably 0.2-3.0%. In specific implementation, it can be set to 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, etc.
[0076] Tests show that when the content of the second surfactant in the drug-containing sustained-release portion is less than 0.1%, the indobufen active ingredient cannot be fully dissolved within 24 hours, resulting in drug waste and may not meet the requirements of the treated patients; when the content of the second surfactant in the drug-containing sustained-release portion is greater than 5%, the release rate of the indobufen active ingredient is too fast, which has an adverse effect on the long-term effect of the drug. It can be seen that the amount of the second surfactant used in the present invention can increase the dissolution rate of the indobufen active ingredient in the drug-containing sustained-release portion, so that the active ingredient is completely dissolved and released, which is beneficial to the in vivo absorption of the drug.
[0077] In some embodiments, the content of the first indobufen active ingredient in the drug-containing immediate-release portion is 10-30% by weight, preferably 15-25%, for example, it can be set to 15%, 16%, 20%, 25%, 26.4%, etc.; the content of the second indobufen active ingredient in the drug-containing sustained-release portion is 15-35%, preferably 20-30%, and in specific implementation, it can be set to 20%, 22%, 22.17%, 25%, 26.67%, 30%, etc.
[0078] Tests show that the indobufen active ingredient content ratio of the present invention can ensure that the indobufen active ingredient in the rapid-release portion of the drug can meet the purpose of rapid administration to patients to achieve rapid onset of action, and can also ensure that the indobufen active ingredient in the rapid-release portion of the drug can meet the purpose of long-lasting effect on patients, thereby facilitating the in vivo absorption of the drug and improving the stability of bioavailability.
[0079] In some embodiments, the disintegrant is selected from one or more of low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, calcium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and pregelatinized starch, preferably sodium carboxymethyl starch.
[0080] In some embodiments, the content of disintegrant in the drug-containing rapid-release portion is 2-8% by weight, preferably 3-5%. In specific implementation, it can be set to 2.0%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 6.0%, 7.0%, 8.0%, etc.
[0081] In some embodiments, the sustained-release material is selected from one or more of hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, xanthan gum, sodium alginate, carbomer or polyethylene oxide, preferably hydroxypropyl methylcellulose.
[0082] In some embodiments, the content of sustained-release material in the drug-containing sustained-release portion is 10-50% by weight, preferably 20-40%. In specific implementation, it can be set to 10%, 20%, 25%, 30%, 35%, 40%, 50%, etc.
[0083] In some embodiments, the first filler is selected from one or more of lactose, microcrystalline cellulose, mannitol, starch or pregelatinized starch, preferably microcrystalline cellulose and lactose.
[0084] In some embodiments, the content of the first filler in the drug-containing immediate-release portion is 40-80% by weight, preferably 50-70%. In specific implementation, it can be set to 40%, 50%, 55%, 60%, 65%, 70%, 80%, etc.
[0085] In some embodiments, the second filler is selected from one or more of lactose, microcrystalline cellulose, mannitol, starch or pregelatinized starch, preferably microcrystalline cellulose and lactose.
[0086] In some embodiments, the content of the second filler in the drug-containing sustained-release portion is 20-60% by weight, preferably 30-50%. In specific implementation, it can be set to 20%, 30%, 35%, 40%, 45%, 50%, 60%, etc.
[0087] In some embodiments, the first binder is selected from one or more of hypromellose, polyvinylpyrrolidone, hypromellose or hydroxypropyl cellulose, preferably hypromellose.
[0088] In some embodiments, the content of the first adhesive in the drug-containing rapid-release portion is 2-10% by weight, preferably 3-5%. In specific implementation, it can be set to 2%, 3%, 3.5%, 4%, 4.5%, 5%, 6%, 7%, 8%, 9%, 10%, etc.
[0089] In some embodiments, the second binder is selected from one or more of hypromellose, polyvinylpyrrolidone, hypromellose or hydroxypropyl cellulose, preferably hypromellose.
[0090] In some embodiments, the content of the second adhesive in the drug-containing sustained-release portion is 2-10% by weight, preferably 3-5%. In specific implementation, it can be set to 2%, 3%, 3.5%, 4%, 4.5%, 5%, 6%, 7%, 8%, 9%, 10%, etc.
[0091] In some embodiments, the first lubricant is selected from one or more of talc, hydrogenated vegetable oil, sodium stearyl fumarate or magnesium stearate, and more preferably, magnesium stearate is used.
[0092] In some embodiments, the content of the first lubricant in the drug-containing immediate-release portion is 0.2-3% by weight, preferably 0.5-2.0%. In specific implementation, it can be set to 0.2%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, etc.
[0093] In some embodiments, the second lubricant is selected from one or more of talc, hydrogenated vegetable oil, sodium stearyl fumarate or magnesium stearate, and more preferably, magnesium stearate is used.
[0094] In some embodiments, the content of the second lubricant in the drug-containing sustained-release portion is 0.2-3%, preferably 0.5-2.0%, measured by weight percentage. In specific implementation, it can be set to 0.2%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, etc.
[0095] The second aspect of the present invention is to provide a method for preparing an oral solid preparation of indobufen, comprising the following steps:
[0096] S1. weighing the active ingredient of indobufen, filler, disintegrant and binder in the drug-containing immediate-release part, sieving and premixing to obtain a drug-containing immediate-release premix excipient, adding a surfactant to the drug-containing immediate-release premix excipient for wet granulation, then sequentially performing wet granulation, drying and dry granulation, and finally adding a prescribed amount of lubricant for total mixing to obtain drug-containing immediate-release granules;
[0097] The active ingredient of the drug-containing sustained-release indobufen, a filler, a disintegrant, and a binder are weighed, sieved, and premixed to obtain a drug-containing sustained-release premix excipient, a surfactant is added to the drug-containing sustained-release premix excipient for wet granulation, and then wet granulation, drying, and dry granulation are sequentially performed, and finally a prescribed amount of lubricant is added for total mixing to obtain drug-containing sustained-release granules;
[0098] S2. Place the prescribed amount of drug-containing sustained-release layer granules in the tablet press die and pre-press; then place the prescribed amount of drug-containing immediate-release layer granules in the die, press into tablets, and then coat and package to obtain indobufen oral solid preparations.
[0099] Wherein, in step S2, the drug-containing immediate-release particles form the drug-containing immediate-release part of the indobufen oral solid preparation, and the drug-containing sustained-release particles form the drug-containing sustained-release part of the indobufen oral solid preparation.
[0100] In some embodiments, in step S1, the method of adding the first surfactant is: after dissolving the first surfactant in a solvent to prepare a mixed solution, adding it to the drug-containing immediate-release premix excipient by spraying; and / or, the method of adding the second surfactant is: after dissolving the second surfactant in a solvent to prepare a mixed solution, adding it to the drug-containing sustained-release premix excipient by spraying.
[0101] Tests have found that the present invention uses atomization to add surfactants, which can improve the solubility of the indobufen active ingredient, make the dissolution and release more complete, facilitate the absorption of the drug in the body, and improve the stability of bioavailability.
[0102] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0103] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, methods and instruments used are conventional materials, reagents, methods and instruments in the art unless otherwise specified, and can be obtained through commercial channels by those skilled in the art.
[0104] Example 1
[0105] This embodiment provides an oral solid preparation of indobufen, the formula of which is shown in Table 1:
[0106] Table 1. Formula composition of indobufen oral solid preparation of Example 1
[0107]
[0108] The preparation process of this embodiment is as follows:
[0109] S100. Weigh the active ingredient of indobufen, filler, disintegrant and binder in the drug-containing immediate-release part according to the weight ratio in Table 1, sieve and pre-mix to obtain a drug-containing immediate-release premix excipient, dissolve the surfactant in water to prepare a mixed solution, and then add the mixed solution to the drug-containing immediate-release premix excipient in a spraying manner for wet granulation, then sequentially perform wet granulation, drying and dry granulation, and finally add the prescribed amount of lubricant for total mixing to obtain drug-containing immediate-release granules;
[0110] The active ingredient of the drug-containing sustained-release indobufen, a filler, a disintegrant, and a binder are weighed, sieved, and premixed to obtain a drug-containing sustained-release premix excipient, a surfactant is dissolved in water to prepare a mixed solution, and then the mixed solution is added to the drug-containing sustained-release premix excipient in a spraying manner for wet granulation, and then wet granulation, drying, and dry granulation are sequentially performed, and finally a prescribed amount of lubricant is added for total mixing to obtain drug-containing sustained-release granules;
[0111] S200. Place the prescribed amount of drug-containing sustained-release layer granules in the die of a tablet press and pre-press them; then place the prescribed amount of drug-containing immediate-release layer granules in the die, press them into tablets, and then coat and package them to obtain an oral solid preparation of indobufen.
[0112] Example 2
[0113] This embodiment provides an oral solid preparation of indobufen. Compared with Example 1, the difference of this embodiment is mainly that the surfactant in the drug-containing immediate-release part and the drug-containing sustained-release part is replaced with polyethylene glycol, and the content of the surfactant is adjusted to 2.5%. The specific formula is shown in Table 2:
[0114] Table 2. Formula composition of indobufen oral solid preparation of Example 2
[0115]
[0116] Preparation process: The preparation process of this embodiment is the same as that of embodiment 1.
[0117] Example 3
[0118] This embodiment provides an oral solid preparation of indobufen. Compared with Example 1, the difference of this embodiment is mainly that the surfactant in the drug-containing immediate-release part and the drug-containing sustained-release part is changed to sodium dodecyl sulfate, and the content of the surfactant is adjusted to 5.0%. The specific formula is shown in Table 3:
[0119] Table 3. Formula composition of indobufen oral solid preparation of Example 3
[0120]
[0121]
[0122] Preparation process: The preparation process of this embodiment is the same as that of embodiment 1.
[0123] Example 4
[0124] This embodiment provides an oral solid preparation of indobufen. Compared with Example 1, the difference of this embodiment is mainly that the amount of indobufen active ingredient in the drug-containing immediate-release part and the drug-containing sustained-release part is different, and the ratio of indobufen in the drug-containing immediate-release part to indobufen in the drug-containing sustained-release part is adjusted to 1:2 based on actual weight. In addition, different sustained-release materials are selected. The specific formula is shown in Table 4:
[0125] Table 4. Formula composition of indobufen oral solid preparation of Example 4
[0126]
[0127] Preparation process: The preparation process of this embodiment is the same as that of embodiment 1.
[0128] Example 5
[0129] This embodiment provides an oral solid preparation of indobufen. Compared with Example 1, the difference of this embodiment is mainly that the amount of indobufen active ingredient in the drug-containing immediate-release part and the drug-containing sustained-release part is different, and the ratio of indobufen in the drug-containing immediate-release part to indobufen in the drug-containing sustained-release part is adjusted to 1:4 based on actual weight. In addition, different sustained-release materials are selected. The specific formula is shown in Table 5:
[0130] Table 5. Formula composition of indobufen oral solid preparation of Example 5
[0131]
[0132] Preparation process: The preparation process of this embodiment is the same as that of embodiment 1.
[0133] Comparative Example 1
[0134] This comparative example provides an oral solid preparation of indobufen, the formulation ingredients and proportions of which are exactly the same as those of Example 2, the only difference being that in step S100 of the preparation process, the surfactant in this comparative example is directly added to other excipients instead of being added by atomization.
[0135] Comparative Example 2
[0136] This comparative example provides an oral solid preparation of indobufen. Compared with Example 1, the difference of this comparative example is that no surfactant is added to the drug-containing rapid-release part and the drug-containing sustained-release part. The specific formula is shown in Table 6:
[0137] Table 6. Comparative Example 2 Indobufen oral solid preparation formula composition table
[0138]
[0139]
[0140] Preparation process: The preparation process of this comparative example is the same as that of Example 1.
[0141] Comparative Example 3
[0142] This comparative example provides an oral solid preparation of indobufen. Compared with Example 3, the difference of this comparative example is only that the amount of surfactant used in the drug-containing rapid-release part and the drug-containing sustained-release part is different. The specific formula is shown in Table 7:
[0143] Table 7. Comparative Example 3 Indobufen oral solid preparation formulation composition table
[0144]
[0145] Preparation process: The preparation process of this comparative example is the same as that of Example 1.
[0146] Comparative Example 4
[0147] This comparative example provides an oral solid preparation of indobufen. Compared with Example 1, the difference of this comparative example is mainly that the amount of indobufen active ingredient in the drug-containing immediate-release part and the drug-containing sustained-release part is different, and the ratio of indobufen in the drug-containing immediate-release part to indobufen in the drug-containing sustained-release part is adjusted to 1:1 based on actual weight. The specific formula is shown in Table 8:
[0148] Table 8. Comparative Example 4 Indobufen oral solid preparation formulation composition table
[0149]
[0150]
[0151] Preparation process: The preparation process of this comparative example is the same as that of Example 1.
[0152] Comparative Example 5
[0153] This comparative example provides an oral solid preparation of indobufen. Compared with Example 1, the difference of this comparative example is mainly that the amount of indobufen active ingredient in the drug-containing immediate-release part and the drug-containing sustained-release part is different, and the ratio of indobufen in the drug-containing immediate-release part to indobufen in the drug-containing sustained-release part is adjusted to 1:5 based on actual weight. The specific formula is shown in Table 9:
[0154] Table 9. Formula composition of indobufen oral solid preparation of comparative example 5
[0155]
[0156] Preparation process: The preparation process of this comparative example is the same as that of Example 1.
[0157] Comparative Example 6
[0158] This comparative example provides an oral solid preparation of indobufen. Compared with Example 1, the difference of this comparative example is mainly that a different sustained-release material is selected and the amount of the sustained-release material is different. The specific formula is shown in Table 10:
[0159] Table 10. Formula composition of indobufen oral solid preparation of comparative example 6
[0160]
[0161] Preparation process: The preparation process of this comparative example is the same as that of Example 1.
[0162] Comparative Example 7
[0163] This comparative example provides an oral solid preparation of indobufen. Compared with Example 1, the formulation of this comparative example is exactly the same, and the main difference is that the amount of sustained-release material is different. The specific formula is shown in Table 11:
[0164] Table 11. Formula composition of indobufen oral solid preparation of comparative example 7
[0165]
[0166]
[0167] Preparation process: The preparation process of this comparative example is the same as that of Example 1.
[0168] Comparative Example 8
[0169] This comparative example provides an oral solid preparation of indobufen. Compared with Example 1, the formulation of this comparative example is exactly the same, and the main difference is that the amount of sustained-release material is different. The specific formula is shown in Table 12:
[0170] Table 12. Formula composition of indobufen oral solid preparation of comparative example 8
[0171]
[0172] Preparation process: The preparation process of this comparative example is the same as that of Example 1.
[0173] Test Case
[0174] Dissolution Testing
[0175] Dissolution conditions: 37℃±0.5℃, basket method, 75rpm, pH7.6 phosphate buffer, 1000ml.
[0176] Medium preparation: Weigh 6.805 g of potassium dihydrogen phosphate and 1.696 g of sodium hydroxide into 1000 ml of water, dissolve by ultrasonication (if necessary, adjust the pH of the solution to 7.60±0.05 with phosphoric acid or sodium hydroxide solution), and degas.
[0177] Indobufen dissolution requirements are shown in Table 13:
[0178] Table 13. Indobufen dissolution qualification standard table:
[0179] time 0.5h 1h 18h 24h Dissolution % ≥20 ≤50 ≥80 ≥95
[0180] The indobufen oral solid preparations of Examples 1-5 and Comparative Examples 1-8 were tested for indobufen dissolution, and the results are shown in Table 14:
[0181] Table 14. Indobufen dissolution statistics
[0182]
[0183] The dissolution curves of the indobufen oral solid preparations of Examples 1-5 and Comparative Examples 1-8 are as follows: Figure 1-13 shown.
[0184] Refer to the formula and preparation process of Examples 1-5 and Comparative Examples 1-8, as well as Tables 13, 14, Figure 1-13 Dissolution test results:
[0185] 1) Comparative Example 1 is compared with Example 2, and the formula is exactly the same. The only difference is that in the preparation process, Example 2 uses atomization to add the surfactant, while Comparative Example 1 uses direct addition, resulting in the solubility of indobufen in Comparative Example 1 decreasing from 95.7% to 90.1% in 24 hours, which does not meet the dissolution qualification standard requirements shown in Table 13. This leads to insufficient utilization of the active ingredient of indobufen by the patient after taking the preparation, which has an adverse effect on the therapeutic effect. It can be seen that the present invention uses atomization to add the surfactant, which can improve the solubility of indobufen, thereby improving the bioavailability after taking it.
[0186] 2) The only difference between Comparative Example 2 and Example 1 is that no surfactant is added to the drug-containing immediate-release portion and the drug-containing sustained-release portion. Referring to Table 14, it can be seen that the solubility of indobufen in Comparative Example 2 at each time point is significantly reduced. In particular, the solubility of indobufen at the two test points of 18h and 24h is lower than the dissolution qualification standard requirements shown in Table 13, which has an adverse effect on the long-term effect of the preparation. In addition, the only difference between Comparative Example 3 and Example 3 is that the amount of surfactant added to the drug-containing immediate-release part and the drug-containing sustained-release part is adjusted from 5% to 6%. Referring to Table 14, it is found that the solubility of Comparative Example 3 at 1 hour exceeds the qualified standard requirements, which may cause the indobufen in the immediate-release part to be released too quickly in the early stage, and the indobufen to be absorbed too quickly in the early stage, affecting the later sustained-release effect; while Examples 1-5 set the surfactant content of the drug-containing immediate-release part and the drug-containing sustained-release part within the range of 0.1-5.0%, especially within the range of 0.5-5.0%. It can be seen that the amount of surfactant added in the present invention can ensure that the solubility of indobufen in each time period meets the qualified standard requirements as shown in Table 13, thereby achieving the purpose of rapid onset and long-lasting effect for the user.
[0187] 3) Compared with Example 1, the main difference between Comparative Examples 4 and 5 is that the dosage of the indobufen active ingredient in the drug-containing immediate-release portion and the drug-containing sustained-release portion is different, which causes the weight ratio of indobufen in the drug-containing immediate-release portion to that in the drug-containing sustained-release portion to be different. Among them, the ratio of indobufen in the drug-containing immediate-release portion to that in the drug-containing sustained-release portion in Comparative Example 4 is adjusted to 1:1, which leads to an excessively high content of indobufen in the drug-containing immediate-release portion. Referring to Table 14, it can be seen that the solubility of indobufen in Comparative Example 4 at 0.5h and 1h is significantly improved, among which the solubility at 1h is 69.10%, which significantly exceeds the qualified standard of ≤50%. This may cause the indobufen in the immediate-release portion to be released too quickly in the early stage after the patient takes the preparation, and the indobufen is absorbed too quickly in the early stage, affecting the later sustained-release effect. In addition, the ratio of indobufen in the immediate-release portion of comparative example 5 to indobufen in the sustained-release portion of the drug is adjusted to 1:5, resulting in too low an indobufen content in the immediate-release portion, while too high an indobufen content in the sustained-release portion of the drug. Referring to Table 14, it can be seen that the solubility of indobufen in comparative example 5 at 0.5 h is only 18.90%, which is lower than the qualified standard requirement of ≥20%. At the same time, the solubility of indobufen at 24 h is 93.50%, which is also lower than the qualified standard requirement of ≥95%. This may cause insufficient dosage of the immediate-release portion of the preparation, which cannot meet the requirement of rapid onset of effect on patients, and the insufficient bioavailability of indobufen in the sustained-release portion may fail to achieve the purpose of sustained effect. It can be seen that the present invention sets the weight ratio of indobufen in the immediate-release portion to indobufen in the sustained-release portion to be 1:2-1:4, so that after the patient ingests the indobufen oral solid preparation, the indobufen active ingredient in the immediate-release portion is sufficient to achieve a rapid effect on the patient, and at the same time, the indobufen active ingredient in the sustained-release portion can also meet the requirement of long-term administration of the patient.
[0188] 4) Comparative Example 6 is different from Example 1 only in that ethyl cellulose is used as the sustained-release material of the drug-containing sustained-release part, and the other components are the same as those of Example 1. Referring to Table 14, it can be seen that the indobufen dissolution rates of Comparative Example 6 at 18h and 24h are only 78.76% and 86.12%, respectively, which are lower than the qualified standard requirements of ≥80% and ≥95%, respectively, which leads to insufficient bioavailability of indobufen in the sustained-release part and cannot achieve the purpose of sustained effect. It can be seen that the sustained-release material selected by the present invention can meet the sustained-release requirements of indobufen within 24h, and can ensure that the dissolution meets the qualified standard requirements as shown in Table 13, and achieve higher bioavailability.
[0189] 5) Compared with Example 1, the components of Comparative Examples 7-8 are exactly the same, and the only difference is the amount of sustained-release material used. Among them, the content of sustained-release material in Comparative Example 7 is 5%. Referring to Table 14, it can be seen that the solubility of indobufen in Comparative Example 7 at 0.5h and 1h reaches 62.10% and 76.20%, respectively, and especially the solubility at 1h significantly exceeds the qualified standard of ≤50%, which easily leads to too fast administration speed, and there is a great safety hazard for patients taking the preparation. In addition, due to the too fast dissolution rate of indobufen, sustained-release administration cannot be achieved, and it is difficult to achieve the purpose of continuous treatment of patients; the content of sustained-release material in Comparative Example 8 is 60%. Continuing to refer to Table 14, it can be seen that the solubility of indobufen in Comparative Example 8 at 18h and 24h decreases to 79.90% and 86.90%, respectively, which are lower than the qualified standard requirements of ≥80% and ≥95%, respectively, which leads to insufficient bioavailability of indobufen in the sustained-release part and the purpose of sustained effect cannot be achieved. It can be seen that the present invention sets the dosage of sustained-release material to 10-50% of the weight of the drug-containing immediate-release portion, which can ensure that the dissolution rate of indobufen in both the immediate-release time interval and the sustained-release time interval can meet the qualified standard requirements, thereby ensuring that the indobufen oral solid preparation can meet the requirements of both rapid and long-lasting effects on patients.
[0190] In summary, the indobufen oral solid preparation of the present invention has the characteristics of biphasic release, and can solve the problems of unsustainable efficacy, poor patient compliance, and insufficient clinical safety.
[0191] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the technical solution of the present invention, and are not intended to limit the specific implementation methods of the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the claims of the present invention shall be included in the protection scope of the claims of the present invention.
Claims
1. An oral solid preparation of indobufen, characterized in that: It includes a drug-containing rapid-release portion and a drug-containing sustained-release portion; The drug-containing immediate-release portion includes a first indobufen active ingredient, a first filler, a first surfactant, a first binder, a first lubricant and a disintegrant; The drug-containing sustained-release portion comprises a second indobufen active ingredient, a second filler, a second surfactant, a second adhesive, a second lubricant and a sustained-release material.
2. The oral solid preparation of indobufen according to claim 1, characterized in that The weight ratio of the first indobufen active ingredient to the second indobufen active ingredient is 1:2-1:
4.
3. The oral solid preparation of indobufen according to claim 1, characterized in that The first surfactant is selected from one or more of Tween-80, polyoxyethylene castor oil, polyethylene glycol, polysorbates, glycerol, sodium lauryl sulfate, monocaprylic acid glyceryl, stearic acid macrogol glyceryl, caprylic and capric mono- and di-glycerides; and / or, In terms of weight percentage, the content of the first surfactant in the drug-containing rapid-release portion is 0.1-5%; and / or, The second surfactant is selected from one or more of Tween-80, polyoxyethylene castor oil, polyethylene glycol, polysorbates, glycerol, sodium lauryl sulfate, monocaprylic acid glyceryl, stearic acid macrogol glyceryl, caprylic acid capric acid mono- and di-glycerides; and / or, Measured by weight percentage, the content of the second surfactant in the drug-containing sustained-release portion is 0.1-5%.
4. The oral solid preparation of indobufen according to claim 1, characterized in that: The content of the first indobufen active ingredient in the drug-containing immediate-release portion is 10-30% by weight; and / or, The content of the second indobufen active ingredient in the drug-containing sustained-release portion is 15-35%.
5. The indobufen oral solid preparation according to any one of claims 1 to 4, characterized in that: The disintegrant is selected from one or more of low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, calcium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and pregelatinized starch; and / or, The content of the disintegrant in the drug-containing rapid-release portion is 2-8% by weight; and / or, The sustained-release material is selected from one or more of hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, xanthan gum, sodium alginate, carbomer or polyethylene oxide; and / or, Calculated by weight percentage, the content of the sustained-release material in the drug-containing sustained-release portion is 10-50%.
6. The indobufen oral solid preparation according to any one of claims 1 to 4, characterized in that: The first filler is selected from one or more of lactose, microcrystalline cellulose, mannitol, starch or pregelatinized starch; and / or, In terms of weight percentage, the content of the first filler in the drug-containing immediate-release portion is 40-80%; and / or, The second filler is selected from one or more of lactose, microcrystalline cellulose, mannitol, starch or pregelatinized starch; and / or, Calculated by weight percentage, the content of the second filler in the drug-containing sustained-release portion is 20-60%.
7. The indobufen oral solid preparation according to any one of claims 1 to 4, characterized in that: The first binder is selected from one or more of hydroxypropyl methylcellulose, polyvinyl pyrrolidone, hydroxypropyl methylcellulose or hydroxypropyl cellulose; and / or, In terms of weight percentage, the content of the first binder in the drug-containing immediate-release portion is 2-10%; and / or, The second binder is selected from one or more of hydroxypropyl methylcellulose, polyvinyl pyrrolidone, hydroxypropyl methylcellulose or hydroxypropyl cellulose; and / or, Measured by weight percentage, the content of the second binder in the drug-containing sustained-release portion is 2-10%.
8. The indobufen oral solid preparation according to any one of claims 1 to 4, characterized in that: The first lubricant is selected from one or more of talc, hydrogenated vegetable oil, sodium stearyl fumarate or magnesium stearate; and / or, In terms of weight percentage, the content of the first lubricant in the drug-containing immediate-release portion is 0.2-3%; and / or, The second lubricant is selected from one or more of talc, hydrogenated vegetable oil, sodium stearyl fumarate or magnesium stearate; and / or, Measured by weight percentage, the content of the second lubricant in the drug-containing sustained-release portion is 0.2-3%.
9. A method for preparing the indobufen oral solid preparation according to any one of claims 1 to 8, characterized in that: The steps include: The first indobufen active ingredient, the first filler, the first disintegrant, and the first binder are sieved and premixed to obtain a drug-containing immediate-release premix excipient, the first surfactant is added to the drug-containing immediate-release premix excipient for wet granulation, and then wet granulation, drying, and dry granulation are sequentially performed, and finally the first lubricant is added for total mixing to obtain drug-containing immediate-release granules; The second indobufen active ingredient, the second filler, the second disintegrant, and the second binder are pre-mixed after screening to obtain a drug-containing sustained-release premix excipient, the second surfactant is added to the drug-containing sustained-release premix excipient for wet granulation, and then wet granulation, drying, and dry granulation are sequentially performed, and finally the second lubricant is added for total mixing to obtain drug-containing sustained-release granules; The prescribed amount of drug-containing sustained-release layer particles are placed in a tablet press die and pre-pressed; the prescribed amount of drug-containing immediate-release layer particles are placed in the die and pressed into tablets, followed by coating and packaging, thereby obtaining an oral solid preparation of indobufen; The drug-containing rapid-release particles form the drug-containing rapid-release part of the indobufen oral solid preparation, and the drug-containing sustained-release particles form the drug-containing sustained-release part of the indobufen oral solid preparation.
10. The method according to claim 9, characterized in that Adding the first surfactant to the drug-containing immediate-release premix excipient comprises: dissolving the first surfactant in a solvent to prepare a mixed solution, and then adding the mixed solution to the drug-containing immediate-release premix excipient in a spraying manner; and / or, Adding the second surfactant to the drug-containing sustained-release premix excipient comprises: dissolving the second surfactant in a solvent to prepare a mixed solution, and then adding the mixed solution to the drug-containing sustained-release premix excipient in a spraying manner.
Citation Information
Patent Citations
An indobufen solid dosage form and its preparation method
CN105853364B
Cited By
Indobufen freeze-dried orally disintegrating tablet and preparation method thereof
CN120884549A
A freeze-dried indobufen orally disintegrating tablet and a preparation method thereof
CN120884549B
Indobufen oral soluble film and preparation method thereof
CN121059572A
Controlled-release pharmaceutical composition, preparation method therefor, and use thereof
WO2026179881A1
